Abstract
Apoptosis, or programmed cell death, is a cell suicide process with a major role in development and homeostasis in vertebrates and invertebrates. Dysregulation of apoptosis leading to early cell death or the absence of normal cell death contributes to a number of disease conditions including neurodegenerative diseases and cancer. Inhibition of apoptosis enhances the survival of cancer cells and facilitates their escape from immune surveillance and cytotoxic therapies. Inhibitor of apoptosis (IAP) proteins, a family of anti-apoptotic regulators that block cell death in response to diverse stimuli through interactions with inducers and effectors of apoptosis are among the principal molecules contributing to this phenomenon. IAP proteins are expressed in the majority of human malignancies at elevated levels and play an active role in promoting tumor maintenance through the inhibition of cellular death and participation in signaling pathways associated with malignancies. Herein, the role of IAP proteins in cancer and strategies toward targeting IAP proteins for therapeutic intervention will be discussed.
Current Cancer Drug Targets
Title: Targeting IAP (Inhibitor of Apoptosis) Proteins for Therapeutic Intervention in Tumors
Volume: 8 Issue: 2
Author(s): Domagoj Vucic
Affiliation:
Abstract: Apoptosis, or programmed cell death, is a cell suicide process with a major role in development and homeostasis in vertebrates and invertebrates. Dysregulation of apoptosis leading to early cell death or the absence of normal cell death contributes to a number of disease conditions including neurodegenerative diseases and cancer. Inhibition of apoptosis enhances the survival of cancer cells and facilitates their escape from immune surveillance and cytotoxic therapies. Inhibitor of apoptosis (IAP) proteins, a family of anti-apoptotic regulators that block cell death in response to diverse stimuli through interactions with inducers and effectors of apoptosis are among the principal molecules contributing to this phenomenon. IAP proteins are expressed in the majority of human malignancies at elevated levels and play an active role in promoting tumor maintenance through the inhibition of cellular death and participation in signaling pathways associated with malignancies. Herein, the role of IAP proteins in cancer and strategies toward targeting IAP proteins for therapeutic intervention will be discussed.
Export Options
About this article
Cite this article as:
Vucic Domagoj, Targeting IAP (Inhibitor of Apoptosis) Proteins for Therapeutic Intervention in Tumors, Current Cancer Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/156800908783769373
DOI https://dx.doi.org/10.2174/156800908783769373 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews A Highly Sensitive Chemiluminescence Method and Application in Rapid Pharmacokinetic Study of Matrine in Rat Plasma
Current Pharmaceutical Analysis Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Preface (Proceedings of the VII Immunonutrition Workshop “Eating for Preventing” [Carovigno, (Italy) May 1-3, 2014] – First Part-)
Endocrine, Metabolic & Immune Disorders - Drug Targets RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists
Current Topics in Medicinal Chemistry Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry tcaSIM: A Simulation Program for Optimal Design of 13C Tracer Experiments for Analysis of Metabolic Flux by NMR and Mass Spectroscopy
Current Metabolomics Anticancer Effects of Garlic and Garlic-derived Compounds for Breast Cancer Control
Anti-Cancer Agents in Medicinal Chemistry RNA Sequencing and Transcriptome Analyses for Cercis Gigantean
Current Bioinformatics Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology Use of Positron Emission Tomography for Target Volume Definition
Current Radiopharmaceuticals Editorial [ DNA Repair as a Target for Anti-Cancer Therapy Guest Editor: Robert M. Brosh Jr. ]
Anti-Cancer Agents in Medicinal Chemistry